In focus · trending topic

AXS-05

42 stories · following the connections

Axsome Therapeutics Reports Second Quarter 2017 Financial Results

By Nasdaq OMXAug 9, 2017, 11:00 AM UTC

Axsome Therapeutics Initiates Phase 2/3 Trial of AXS-05 for Alzheimer’s Disease Agitation

By Nasdaq OMXJul 17, 2017, 11:00 AM UTC

Axsome Therapeutics Reports First Quarter 2017 Financial Results

By Nasdaq OMXMay 9, 2017, 11:02 AM UTC

Axsome Therapeutics Reports First Quarter 2017 Financial Results

By Nasdaq OMXMay 9, 2017, 11:02 AM UTC

Axsome Therapeutics Reports First Quarter 2017 Financial Results

By Nasdaq OMXMay 9, 2017, 11:02 AM UTC

Axsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Alzheimer’s Disease Agitation

By Nasdaq OMXMay 8, 2017, 11:01 AM UTC

Axsome Therapeutics Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares

By Nasdaq OMXMar 29, 2017, 11:01 AM UTC

Axsome Therapeutics to Present at the 16th Annual Needham Healthcare Conference

By Nasdaq OMXMar 23, 2017, 11:00 AM UTC